The DOI matches its Crossref record.
Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol
Open accessAbstract
BACKGROUND: The oral dual endothelin receptor antagonist bosentan improves exercise capacity and delays clinical worsening in patients with pulmonary arterial hypertension, but its use could delay starting intravenous epoprostenol, a life saving treatment. METHODS: Survival in patients with functional class III idiopathic pulmonary arterial hypertension (PAH) treated with bosentan in clinical trials was compared with historical data from similar patients treated with epoprostenol in the clinic. Statistical methods were used to adjust for possible underlying differences between the two groups. RESULTS: Baseline factors for the 139 patients treated with bosentan and the 346 treated with epoprostenol suggested that the epoprostenol cohort had more severe disease-that is, a lower cardiac index (2.01 v 2.39 l/min/m2) and higher pressures and resistance. Kaplan-Meier survival estimates after 1 and 2 years were 97% and 91%, respectively, in the bosentan cohort and 91% and 84% in the epoprostenol cohort. Cox regression analyses adjusting for differences in baseline factors showed a greater probability of death in the epoprostenol cohort (hazard ratio 2.2 (95% confidence interval 1.2 to 4.0) in the model adjusted for haemodynamics). Alternative regression analyses and analyses to adjust for different data collection dates gave consistently similar results. When matched cohorts of 83 patients each were selected, survival estimates were similar. In the bosentan cohort 87% and 75% of patients followed for 1 and 2 years, respectively, remained on monotherapy. CONCLUSIONS: No evidence was found to suggest that initial treatment with oral bosentan, followed by or with the addition of other treatment if needed, adversely affected the long term outcome compared with initial intravenous epoprostenol in patients with class III idiopathic PAH.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
Galiè, N., Humbert, M., Vachiery, J.-L., Gibbs, S., Lang, I., Torbicki, A., Simonneau, G., Peacock, A., Vonk Noordegraaf, A., Beghetti, M., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv317 · Cited by 6,931
Authors/Task Force Members, Galie, N., Hoeper, M. M., Humbert, M., Torbicki, A., Vachiery, J.-L., Barbera, J. A., Beghetti, M., Corris, P., Gaine, S., et al. (2009) · European Heart Journal · doi:10.1093/eurheartj/ehp297 · Cited by 3,846
Galiè, N., Humbert, M., Vachiery, J.-L., Gibbs, S., Lang, I., Torbicki, A., Simonneau, G., Peacock, A., Vonk Noordegraaf, A., Beghetti, M., et al. (2015) · European Respiratory Journal · doi:10.1183/13993003.01032-2015 · Cited by 3,172
ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension
McLaughlin, V. V., Archer, S. L., Badesch, D. B., Barst, R. J., Farber, H. W., Lindner, J. R., Mathier, M. A., McGoon, M. D., Park, M. H., Rosenson, R. S., et al. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.01.004 · Cited by 2,360
Guidelines for the diagnosis and treatment of pulmonary hypertension
(2009) · European Respiratory Journal · doi:10.1183/09031936.00139009 · Cited by 1,300
Diagnosis and Assessment of Pulmonary Arterial Hypertension
Badesch, D. B., Champion, H. C., Gomez Sanchez, M. A., Hoeper, M. M., Loyd, J. E., Manes, A., McGoon, M., Naeije, R., Olschewski, H., Oudiz, R. J., et al. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.04.011 · Cited by 1,138
Writing Committee Members, McLaughlin, V. V., Archer, S. L., Badesch, D. B., Barst, R. J., Farber, H. W., Lindner, J. R., Mathier, M. A., McGoon, M. D., Park, M. H., et al. (2009) · Circulation · doi:10.1161/circulationaha.109.192230 · Cited by 1,093
Medical Therapy For Pulmonary Arterial Hypertension
Badesch, D. B., Abman, S. H., Ahearn, G. S., Barst, R. J., McCrory, D. C., Simonneau, G., & McLaughlin, V. V. (2004) · Chest · doi:10.1378/chest.126.1_suppl.35s · Cited by 829
van Wolferen, S. A., Marcus, J. T., Boonstra, A., Marques, K. M. J., Bronzwaer, J. G. F., Spreeuwenberg, M. D., Postmus, P. E., & Vonk-Noordegraaf, A. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehl477 · Cited by 753
Pulmonary Arterial Hypertension
McLaughlin, V. V., & McGoon, M. D. (2006) · Circulation · doi:10.1161/circulationaha.104.503540 · Cited by 664
Survival in pulmonary arterial hypertension: a reappraisal of the NIH risk stratification equation
Thenappan, T., Shah, S. J., Rich, S., Tian, L., Archer, S. L., & Gomberg-Maitland, M. (2010) · European Respiratory Journal · doi:10.1183/09031936.00072709 · Cited by 493
Medical Therapy for Pulmonary Arterial Hypertension
Badesch, D. B., Abman, S. H., Simonneau, G., Rubin, L. J., & McLaughlin, V. V. (2007) · Chest · doi:10.1378/chest.06-2674 · Cited by 438
2015 ESC/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension
Galiè, N., Humbert, M., Vachiery, J.-L., Gibbs, S., Lang, I., Torbicki, A., Simonneau, G., Peacock, A., Noordegraaf, A. V., Beghetti, M., et al. (2016) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2016.01.002 · Cited by 357
Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil
Barst, R. J., Galie, N., Naeije, R., Simonneau, G., Jeffs, R., Arneson, C., & Rubin, L. J. (2006) · European Respiratory Journal · doi:10.1183/09031936.06.00044406 · Cited by 338
Pulmonary arterial hypertension
Montani, D., Günther, S., Dorfmüller, P., Perros, F., Girerd, B., Garcia, G., Jaïs, X., Savale, L., Artaud-Macari, E., Price, L. C., et al. (2013) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-8-97 · Cited by 314
Self-citationPulmonary Arterial Hypertension
Chin, K. M., & Rubin, L. J. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.01.024 · Cited by 309
Haworth, S. G., & Hislop, A. A. (2009) · Heart · doi:10.1136/hrt.2008.150086 · Cited by 305
Kamat, A. M., Flaig, T. W., Grossman, H. B., Konety, B., Lamm, D., O'Donnell, M. A., Uchio, E., Efstathiou, J. A., & Taylor, J. A. (2015) · Nature Reviews Urology · doi:10.1038/nrurol.2015.58 · Cited by 252
Metadata
- Authors
- Sitbon, O.
- Venue
- Thorax
- Publisher
- BMJ
- Published
- 2005-12-01
- Volume
- 60
- Issue
- 12
- Pages
- 1025-1030
- ISSN
- 0040-6376 (ISSN-L)
- OpenAlex
- W2138117143
- Cited by
- 221
- References
- 0
- FWCI
- 17.76
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.